Phase 2 N=139 Pre-op Rectal ChemoRad +/- Cetuximab
Rectal Cancer
Primary: Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval. — 26.6; 26.7 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 Chemoradiation or Brachytherapy for Rectal Cancer
Rectal Cancer
Primary: Number of Patients With Pathologic Complete Response — 0; 2 Participants
N/A N=63 Non-Operative Management and Early Response Assessment in Rectal Cancer
Adenocarcinoma of the Lower Rectum
Primary: Clinical Complete Response Rate — 36; 2 Participants
Phase 2 N=83 S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 25 percentage of participants — p=0.18
Phase 3 N=486 Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
Colorectal Cancer
Primary: Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on…
Phase 2 N=20 Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Phase 1 N=13 Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer
Rectal Cancer
Primary: The Number of Participants Experiencing Dose Limiting Toxicities (DLT) — 0; 0; 0 Participants
Phase 2 N=27 Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Colorectal Cancer
Primary: Pathologic Response and Complete Response — 3 Participants
N/A N=12 Studies in Patients With Low Anterior Resection Syndrome (LARS)
Anterior Resection Syndrome · Bowel Dysfunction
Primary: Change of Anorectal Pressure Assessed With the Fecobionics Device — 9.8 cmH2O
Phase 2 N=58 NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Rectal Cancer
Primary: Percentage of Organ Preservation — 57 percentage of participants
Phase 2 N=39 Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Colon Cancer · Rectal Cancer
Primary: Incidence of Complete Resection — 13 participants
N/A N=16 Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
Rectal Cancer
Primary: Number of Participants With Pathologic Complete Response — 5 Participants
Phase 1 N=22 Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Rectal Cancer
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0 mg/m^2
Phase 2 N=90 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
Colorectal Cancer
Primary: 3-Year Disease-free Survival — 88.2 percentage of patients
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
Phase 2 N=39 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
Rectal Cancer
Primary: Pathologic Complete Response Rate — 7 participants
Phase 2 N=79 Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
N/A N=35 Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Complete Pathologic Response — 8; 21; 1 participants
Phase 2 N=25 Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Rectal Cancer
Primary: Pathologic Local Tumor Response — 8; 6; 11 Participants
Phase 3 N=225 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
Rectal Mucinous Adenocarcinoma · Rectal Signet Ring Cell Adenocarcinoma · Recurrent Rectal Carcinoma
Primary: 3-year Overall Survival Rate — 0.965; 0.843; 0.870 proportion of patients — p=0.35
Phase 2 N=37 Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Rectal Cancer
Primary: Clinical Complete Response (cCR) — 0.24 Proportion of Participants
Phase 2 N=124 Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)
Medium and Lower Rectal Cancer
Primary: Absence at Day 30 of a Symptomatic Anastomotic Leakage (AL) Among 2SCA — 1 Participants
Phase 2 N=146 Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 10.4; 20.8 percentage of participants
Phase 1 N=18 Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients
Rectal Neoplasms
Primary: Dose Related Toxicity — 1; 0; 0; 3 event
Phase 2 N=80 Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
Rectal Neoplasms
Primary: Rate of T Stage Downstaging — 71 percentage of participants
Phase 2 N=180 Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
Rectal Cancer
Primary: Number of Patients Achieving Pathologic Complete Response (pCR). — 25; 9; 90; 56 Participants
Phase 2 N=135 Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
N/A N=20 Patient-Derived Organoids for Rectal Cancer
Rectum Cancer
Primary: Number of Participants With Biopsies That Form Spherical Organoids — 14 Participants